Oropouche virus (OROV) is a zoonotic arbovirus in the Simbu serogroup of the genus Orthobunyavirus. It is endemic to the Amazon Basin, where it has caused over 30 epidemics and half a million cases since 1961. Recently its geographic range has expanded, with outbreaks in Cuba, Bolivia, and non-Amazonian Brazil (2023). Travel-associated cases have subsequently been reported in North America and Europe1-4. We report the first three UK cases in male travellers returning from Paraty, Brazil, highlighting the virus’s spread within Brazil and globally. Clinically, OROV fever mimics other arboviral infections, with fever, headache, myalgia, and rash. Severe neurologic manifestations including Guillain-Barré syndrome, encephalitis, and meningoencephalitis are reported5-8. Emerging evidence also links maternal infection to adverse foetal outcomes, including miscarriage, microcephaly, and neonatal death, though causality remains unconfirmed9-10. These findings warrant heightened vigilance, particularly in pregnant travellers. Viral RNA is detectable by PCR in blood and urine during the acute febrile illness1,12. Seroconversion occurs within two weeks, with antibodies detectable in serum and cerebrospinal fluid11-13. Assay development to date has been hindered in the UK due to lack of access to positive sample material, and there is limited availability of commercial assays. UK clinicians should be aware of OROV as an emerging risk to travellers. Initial testing is available via submission of blood and urine samples from symptomatic travellers with compatible travel history to the UK’s Rare and Imported Pathogens Laboratory (RIPL). Pregnant individuals with suspected OROV infection should be reported to the UK teratology information service (UKTIS)14.